Institut Bergonie

Site:	Institut Bergonie
Address:	229 Cours Argonne
City:	Bordeaux
State:	Gironde
Zip:	33076
Country:	France

24 trials at this site

Phase	Trial	Trial Status	Site Status [asc]	Drug	NCT#
1/2	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)	Recruiting	Active	Regorafenib + Avelumab	NCT03475953
3	A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment	Unknown	Active	Masitinib, (AB1010)	NCT00812240
3	Masitinib 2nd Line versus Sunitinib in Advanced GIST	Unknown	Active	Masitinib or Sunitinib	NCT01694277
3	Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)	Recruiting	Active	Imatinib	NCT02260505
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
2	A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)	Unknown	Active	Imatinib + Regorafenib	NCT02365441
2	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	Recruiting	Active	LOXO-101	NCT02576431
2	Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)	Completed	Active	Regorafenib (SDH)	NCT02638766
2	Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)	Recruiting	Active	Imatinib	NCT05009927
2	Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)	Recruiting	Active	Lenvatinib	NCT04193553
3	Prospective Multicentric Randomized Study of Glivec® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance	Completed	Closed	Imatinib	NCT00367861
3	Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate	Terminated	Closed	Imatinib	NCT00956072
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
3	Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	Active, not recruiting	Closed	Crenolanib (CP-868,596)	NCT02847429
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
2	Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00568750
2	Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)	Completed	Closed	Pazopanib (Votrient)	NCT01323400

Institut Bergonie

24 trials at this site

Page 1 of 2 | Next | Last